Skip to main content
Figure 1 | Orphanet Journal of Rare Diseases

Figure 1

From: Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome)

Figure 1

Ab+, PAb+, NAb+, and PNAb+ percentages of total subjects by Study Week visit in the primary analysis population. Percent of total subjects that are Ab+, PAb+, NAb+, and PNAb+ by Study Week visit in the primary analysis population. For the Ab+, and NAb+ patients, the percentage of patients who have Abs or NAbs, respectively, at that particular study visit are given. For PAb+ and PNAb+ patients, the cumulative percentage of patients is shown. A patient was considered to be PAb+ or PNAb+ at a given week if, by this time point, the patient had the first of 3 or more consecutive visits at which there were measurable anti-idursulfase Abs/NAbs. Ab+, antibody positive; NAb+, neutralizing antibody positive; PAb+, persistently antibody positive; PNAb+, persistently neutralizing antibody positive.

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172